TrialJournal for immunotherapy of cancer2022

Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial.

Jessica Hochberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.